Madrigal Pharmaceuticals, Inc.'s Rezdiffra saw Q2 net sales soar 55% to $212.8M amid strong growth. EU approval expected by ...

Novo Nordisk (NVO) stock in focus as the company wins FDA accelerated nod for weight loss therapy Wegovy against the liver ...

Bill Sibold, Madrigal Pharmaceuticals CEO, joins 'Fast Money' to discuss Q2 earnings results, the weight loss space and their ...

Novo Nordisk said on Friday the U.S. Food and Drug Administration had granted accelerated approval for its weight-loss drug ...

BOTTOM LINE: The New York Mets head into a matchup against the Seattle Mariners as losers of three games in a row. New York ...

Real Madrid released an official statement recently, expressing their opposition to La Liga’s proposal of hosting a league ...

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, Aug. 12, 2025 at 10:30 A.M. EDT. The ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

Madrigal Pharmaceuticals Inc. MDGL) on Tuesday reported a loss of $42.3 million in its second quarter.

Madrigal will study SYH2086 in combination with Rezdiffra for metabolic dysfunction-associated steatohepatitis, aiming for clinical trials in early 2026.

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

Las Vegas(KLAS)-TV Personality, Peter Madrigal, has launched ‘Reality Network’ providing a one stop shop for all things ...